Citations

Clear

966 citation(s) found for "WONG, R".

The utility of diffusion tractography for speech preservation in laser ablation of the dominant insula: illustrative case
Kerezoudis, Panagiotis , Miller, Kai J. , Kaufmann, Timothy J. , Lehman, Vance T. , Wong‐Kisiel, Lily C.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | May 17, 2021 | Volume: 1 | Issue: 19 | Pages: No page available

10.3171/case21113 | PMID 35854831 Get It

BACKGROUND Open surgical treatment of insular epilepsy holds particular risk of injury to middle cerebral artery branches, the operculum (through retraction), and adjacent language-related white matter tracts in the language-dominant hemisphere. Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a surgical alternative that allows precise lesioning with potentially less operative risk. The authors presented the case of a 13-year-old girl with intractable, MRI-negative, left (dominant hemisphere) insular epilepsy that was treated with LITT. Diffusion tensor imaging (DTI) tractography was used to aid full posterior insular lesioning in the region of stereo electroencephalography–determined seizure onset while avoiding thermal injury to the language-related superior longitudinal fasciculus (SLF)/arcuate fasciculus (AF) and inferior fronto-occipital fasciculus (IFOF). OBSERVATIONS DTI tractography was used successfully in planning insular LITT and facilitated a robust insular ablation with sharp margins at the interfaces with the SLF/AF and IFOF. These tracts were spared, and no neurological deficits were induced through LITT. LESSONS Although it is technically demanding and has important limitations that must be understood, clinically available DTI tractography adds precision and confidence to insular laser ablation when used to protect important language-related white matter tracts.
Identification of Sleep Medicine and Anesthesia Core Topics for Anesthesia Residency: A Modified Delphi Technique Survey
Berezin, Linor, Nagappa, Mahesh , Clivatti, Jefferson, Singh, Mandeep , Auckley, Dennis , Charchaflieh, Jean , Gali, Bhargavi , Joshi, Girish P. , Overdyk, Frank J. , Margarson, Michael, Moon, Tiffany S. , Ramachandran, Satya Krishna , Ryan, Clodagh M. , Won, Christine , Wong, Jean , Fagerlund, Malin Jonsson , Mokhlesi, Babak , Schumann, Roman , Weingarten, Toby N. , Chung, Frances

Mayo Clinic

Anesthesia & Analgesia | April 17, 2021 | Volume: 132 | Issue: 5 | Pages: 1223-1230

10.1213/ane.0000000000005446 | PMID 33857964 Get It

BACKGROUND: Sleep disorders affect up to 25% of the general population and are associated with increased risk of adverse perioperative events. The key sleep medicine topics that are most important for the practice of anesthesiology have not been well-defined. The objective of this study was to determine the high-priority sleep medicine topics that should be included in the education of anesthesia residents based on the insight of experts in the fields of anesthesia and sleep medicine. METHODS: We conducted a prospective cross-sectional survey of experts in the fields of sleep medicine and anesthesia based on the Delphi technique to establish consensus on the sleep medicine topics that should be incorporated into anesthesia residency curricula. Consensus for inclusion of a topic was defined as >80% of all experts selecting “agree” or “strongly agree” on a 5-point Likert scale. Responses to the survey questions were analyzed with descriptive statistical methods and presented as percentages or weighted mean values with standard deviations (SD) for Likert scale data. RESULTS: The topics that were found to have 100% agreement among experts were the influence of opioids and anesthetics on control of breathing and upper airway obstruction; potential interactions of wake-promoting/hypnotic medications with anesthetic agents; effects of sleep and anesthesia on upper airway patency; and anesthetic management of sleep apnea. Less than 80% agreement was found for topics on the anesthetic implications of other sleep disorders and future pathways in sleep medicine and anesthesia. CONCLUSIONS: We identify key topics of sleep medicine that can be included in the future design of anesthesia residency training curricula.
Diabetic ketoacidosis drives COVID‐19 related hospitalizations in children with type 1 diabetes
Alonso, G. Todd , Ebekozien, Osagie , Gallagher, Mary , Rompicherla, Saketh, Lyons, Sarah K. , Choudhary, Abha , Majidi, Shideh , Pinnaro, Catherina T. , Balachandar, Sadana, Gangat, Mariam , Marks, Brynn E. , Creo, Ana L. , Sanchez, Janine , Seeherunvong, Tossaporn, Jimenez‐Vega, Jose , Patel, Neha S. , Gabriel, Liana , Sumpter, Kathryn , Wilkes, Meredith , Rapaport, Robert , Cymbaluk, Anna, Wong, Jenise C. , Sanda, Srinath , Albanese-O’Neill, Anastasia , Alonso, Guy Todd , Creo, Ana , Wilkes, Meredith , Wong, Jenise C , Roberts, Alissa Jeanne Curda , Wood, Jamie

Mayo Clinic

Journal of Diabetes | April 15, 2021 | Volume: 13 | Issue: 8 | Pages: 681-687

10.1111/1753-0407.13184 | PMID 33855813 Get It

AbstractBackgroundDiabetes is a risk factor for poor COVID‐19 outcomes, but pediatric patients with type 1 diabetes are poorly represented in current studies.MethodsT1D Exchange coordinated a US type 1 diabetes COVID‐19 registry. Forty‐six diabetes centers submitted pediatric cases for patients with laboratory confirmed COVID‐19. Associations between clinical factors and hospitalization were tested with Fisher's Exact Test. Logistic regression was used to calculate odds ratios for hospitalization.ResultsData from 266 patients with previously established type 1 diabetes aged <19 years with COVID‐19 were reported. Diabetic ketoacidosis (DKA) was the most common adverse outcome (n = 44, 72% of hospitalized patients). There were four hospitalizations for severe hypoglycemia, three hospitalizations requiring respiratory support (one of whom was intubated and mechanically ventilated), one case of multisystem inflammatory syndrome in children, and 10 patients who were hospitalized for reasons unrelated to COVID‐19 or diabetes. Hospitalized patients (n = 61) were more likely than nonhospitalized patients (n = 205) to have minority race/ethnicity (67% vs 39%, P < 0.001), public insurance (64% vs 41%, P < 0.001), higher A1c (11% [97 mmol/mol] vs 8.2% [66 mmol/mol], P < 0.001), and lower insulin pump and lower continuous glucose monitoring use (26% vs 54%, P < 0.001; 39% vs 75%, P < 0.001). Age and gender were not associated with risk of hospitalization. Higher A1c was significantly associated with hospitalization, with an odds ratio of 1.56 (1.34‐1.84) after adjusting for age, gender, insurance, and race/ethnicity.ConclusionsHigher A1c remained the only predictor for hospitalization with COVID‐19. Diabetic ketoacidosis is the primary concern among this group.
Gastrointestinal defect closure using a novel through-the-scope helix tack and suture device compared to endoscopic clips in a survival porcine model (with video)
Hernandez, Ariosto, Marya, Neil B. , Sawas, Tarek , Rajan, Elizabeth , Gades, Naomi M. , Song, Louis M. Wong Kee , Buttar, Navtej , Wong Kee Song, Louis M, Hernandez, Ariosto, Marya, Neil B. , Dayyeh, Barham K. Abu , Storm, Andrew C.

Mayo Clinic

Endoscopy International Open | April 12, 2021 | Volume: 09 | Issue: 04 | Pages: E572-E577

10.1055/a-1370-9256 | PMID 33860074 Get It

Abstract Background and aims Endoscopic resections are associated with bleeding and perforation and may be managed with through-the-scope (TTS) clips, over-the-scope clips and endoscopic suturing. The aim of this preclinical study was to compare technical success of closure using a novel TTS tissue helix tack and suture device (X-Tack) to TTS clips in a porcine model. Materials and methods Four subjects underwent 40 mucosal resections, diameter range 25–50 mm, in the stomach (n = 24) and colon (n = 16). Closures were randomized to X-Tack (n = 24) or clip (n = 16). Animals underwent weekly endoscopic follow-up for 4 weeks. Results Technical closure with X-Tack was successful in 24 of 24 (100 %) cases and with clips in 13 of 16 cases (81.3 %) (P = 0.0001). One colonic perforation occurred and was successfully managed using X-Tack. The rate of healing was not statistically different between the groups, and all sites healed at 4 weeks including the perforation and were confirmed by histology. Conclusions Compared to TTS clip, X-Tack is superior for effecting large mucosal defect closure, including durable sealing of full-thickness perforation. There was no difference in rate of healing between devices.
Faculty Opinions recommendation of Pneumatic dilation for persistent dysphagia after antireflux surgery, a multicentre single-blind randomised sham-controlled clinical trial.
Song, Louis M. Wong Kee

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739378372.793583976 Get It

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
Privitera, Michael , Bhathal, Hari, Wong, Matthew H. , Cross, J. Helen , Wirrell, Elaine , Marsh, Eric D. , Mazurkiewicz‐Bełdzińska, Maria , Villanueva, Vicente , Checketts, Daniel, Knappertz, Volker, VanLandingham, Kevan, Wirrell, Elaine C , Cross, Helen J , Mazurkiewicz-Bełdzińska, Maria , Wong, Matthew

Mayo Clinic

Epilepsia | April 2, 2021 | Volume: 62 | Issue: 5 | Pages: 1130-1140

10.1111/epi.16878 | PMID 33797076 Get It

AbstractObjectiveTo estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo‐controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox–Gastaut syndrome.MethodsPatients received plant‐derived pharmaceutical formulation of highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 mg/kg/day (CBD20; both trials) or placebo for 14 weeks. Treatment started at 2.5 mg/kg/day for all groups and reached 10 mg/kg/day on Day 7 and 20 mg/kg/day (CBD20 and matching placebo only) on Day 11. Percentage change from baseline in drop seizure frequency was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated.ResultsOverall, 235 patients received CBD (CBD10 [GWPCARE3 only],n = 67; CBD20 [pooled GWPCARE3&4],n = 168) and 161 received placebo. Mean (range) age was 15.3 years (2.6–48.0). Patients had previously discontinued a median (range) of six (0–28) antiepileptic drugs (AEDs) and were currently taking a median of three (0–5) AEDs. Differences in drop seizure reduction between placebo and CBD emerged during the titration period and became nominally significant by Day 6 (p = .008) for pooled CBD treatment groups. Separation between placebo and CBD in ≥50% responder rate emerged by Day 6. Onset of the first reported AE occurred during the titration period in 45% of patients (CBD10, 46%; CBD20, 52%; placebo, 38%). In patients with AEs, resolution occurred within 4 weeks of onset in 53% of placebo and 39% of CBD patients and by end of study in 63% of placebo and 61% of CBD patients.SignificanceTreatment effect (efficacy and AEs) of CBD may occur within 1 week of starting treatment. Although AEs lasted longer for CBD than placebo, most resolved within the 14‐week period.
How to Help Your Patients Enroll in the New-Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES) Family Registry, and Other Rare Epilepsy Registries
Kazazian, Karnig , Wong, Nora , Eschbach, Krista , Moeller, Raquel Farias, Gaspard, Nicolas , Hocker, Sara E. , Hocker, Sara, Eschbach, Krista , Kazazian, Karnig , Gaspard, Nicolas , Kellogg, Marissa , Wong, Nora, Hirsch, Lawrence J. , Gofton, Teneille

Mayo Clinic

Epilepsy Currents | March 26, 2021 | Volume: 21 | Issue: 5 | Pages: 382-384

10.1177/15357597211002869 | PMID 33769129 Get It